Tonix Pharmaceuticals Holding Corp. — Q1 2014 Form 10-Q
Business context and reporting period
Quarter ended March 31, 2014. Tonix was a development-stage, clinical-stage pharmaceutical company with no commercial products and no revenue. Its lead candidate was TNX-102 SL for fibromyalgia; the filing also describes development programs for PTSD, episodic tension-type headache, alcohol-related disorders, and biodefense.
Financial performance and position
- Revenue: None in Q1 2014 or Q1 2013. No cost of goods sold; margins are not applicable.
- Expenses and loss: Research and development expense was $3.550 million, up from $0.741 million; general and administrative expense was $1.619 million, up from $1.260 million. Operating loss was $5.169 million versus $2.001 million; net loss was $5.164 million versus $2.001 million. Basic and diluted loss per share was $0.59 versus $0.93.
- Cash flow: Cash used in operating activities was $4.064 million versus $1.362 million. Investing activities used $2,000. Financing provided $45.412 million, including $40.654 million net proceeds from a stock offering and $4.758 million from warrant exercises.
- Liquidity: The balance sheet reports cash of $49.547 million and working capital of approximately $47.8 million at March 31, compared with cash of $8.202 million at December 31, 2013. Total assets were $50.204 million; total liabilities were $2.281 million.
- Debt: Current liabilities included $280,000 in non-interest-bearing related-party promissory notes, payable on demand after one year from issuance. No other significant debt is reported in the supplied filing text.
Material changes versus Q1 2013
- R&D expense rose 379%, primarily due to increased TNX-102 SL development, manufacturing, and clinical work, plus $858,000 of acquired intellectual property expense. The company also reclassified $184,000 of personnel costs to R&D.
- G&A increased 28%, reflecting higher payroll, professional services, and travel; the filing attributes approximately $70,000 of travel expense to investor-relations activities.
- Net loss increased to $5.164 million from $2.001 million, and operating cash use increased to $4.064 million from $1.362 million.
- Financing materially strengthened the balance sheet: Tonix sold 2,898,550 shares at $15 per share for approximately $40.7 million net and received approximately $4.8 million from warrant exercises. Shares issued and outstanding increased to 9,902,379 from 5,834,083 at year-end.
Outlook, risks, contingencies, and unusual items
- Management said existing cash was expected to fund operating expenses and capital requirements for at least 12 months, while warning that operating losses would continue and cash use and R&D expense were expected to increase significantly. The company anticipated needing additional financing if current funding proved insufficient.
- Management expected topline results from the TNX-102 SL fibromyalgia BESTFIT Phase 2b/3 trial in Q4 2014; enrollment completion was reported on May 12, 2014. Plans included a PTSD Phase 2 trial in Q3 2014 and TNX-201 clinical studies for headache in Q4 2014. These are forward-looking plans, not assured outcomes.
- Clinical development, recruitment, safety, efficacy, regulatory approval, and financing are significant uncertainties. A failed or delayed trial or inability to obtain financing could require program reductions, delays, or relinquishing product rights.
- Outstanding commitments to contract research organizations were approximately $8.0 million at March 31; the company reported an additional approximately $400,000 of commitments entered into through May 12. The amended office lease carries disclosed future minimum payments totaling $1.412 million.
- In March, Tonix acquired smallpox-vaccine and radiation/chemotherapy-protective intellectual-property rights from entities controlled by CEO and Chairman Seth Lederman. Each transaction involved $125,000 cash and 25,000 shares valued at $303,750. These related-party transactions merit review.
- The company reported no material legal proceedings and stated disclosure controls were effective at a reasonable-assurance level, with no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Cash is reported as $49.547 million in the balance sheet and cash-flow statement, but the MD&A states $47.547 million at March 31. The filing text does not reconcile this discrepancy.
- Confirm the working-capital figure: MD&A reports approximately $47.723 million, while the liquidity note describes it as approximately $48.0 million.
- Track BESTFIT results, the remaining fibromyalgia study and long-term safety requirements, and the status and timing of planned PTSD and TNX-201 trials.
- Assess the pace of cash burn against the $8.0 million CRO commitments and management’s stated expectation of sharply rising R&D spending.
- Review the terms, valuation, approval process, and potential conflicts associated with the Lederman-related intellectual-property acquisitions and other related-party arrangements.
- Consider dilution from the public offering, warrant exercises, outstanding warrants and options, and subsequent shareholder approval proposals for additional equity plans.